이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Comparative Analysis of Two Transforaminal Lumbar Interbody Fusion (TLIF) Procedures in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial

2026년 5월 8일 업데이트: Qingchu Li, The Third Affiliated Hospital of Southern Medical University

Comparative Analysis of L-Unitary Soft Endoscope Transforaminal Lumbar Interbody Fusion (LUSE-TLIF) Versus Minimally Invasive Transforaminal Lumbar Interbody Fusion (MIS-TLIF) in the Treatment of Single-Level Lumbar Spinal Stenosis (LSS): A Single-Center, Prospective, Randomized Controlled Trial

Lumbar spinal stenosis (LSS), a common degenerative lumbar condition characterized by low back pain, leg pain, and neurogenic claudication, significantly impairs patients' quality of life. Its prevalence continues to rise with the aging population. For patients who do not respond to conservative treatment, surgical intervention remains a key therapeutic approach, with lumbar interbody fusion (LIF) being a commonly employed procedure. The technique has evolved from posterior lumbar interbody fusion (PLIF) to transforaminal lumbar interbody fusion (TLIF) and, more recently, to minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF). Although MIS-TLIF can effectively reduce tissue trauma and complications, it still faces clinical challenges such as intraoperative visual blind spots and the potential for postoperative chronic back pain associated with reliance on conventional pedicle screws. To address these limitations, our research team independently developed a highly integrated, miniaturized (with an outer diameter of only 1.8 mm), and maneuverable L-Unitary Soft Endoscope (LUSE) minimally invasive system. Its unique design helps avoid obstruction of the surgical field and allows flexible adjustment during the procedure. Currently, there is a lack of clinical efficacy evaluations in China on the use of this LUSE system for TLIF surgery (referred to as LUSE-TLIF) in treating LSS. Therefore, this study aims to systematically compare LUSE-TLIF with the currently mainstream MIS-TLIF, evaluating its safety, efficacy, and clinical outcomes in the treatment of LSS, in order to provide spine surgeons with a novel and potentially superior minimally invasive surgical option.

연구 개요

상세 설명

Lumbar spinal stenosis (LSS) is a common degenerative condition of the lumbar spine. In its narrow definition, LSS primarily refers to central canal stenosis resulting from facet joint hypertrophy and thickening of the ligamentum flavum. Broadly, it also encompasses lateral recess stenosis and bony stenosis within the intervertebral foramen region, categories that some scholars group under lateral canal stenosis. The main symptoms of LSS include low back pain, leg pain, and neurogenic claudication, which impair patients' quality of life and severely limit function, particularly in the elderly. With the aging global population, the prevalence of LSS is rising, affecting approximately 103 million patients worldwide. Treatment options for LSS include both conservative and surgical management. Conservative treatments encompass medication, physical therapy, and lifestyle modifications. However, surgical intervention may be necessary for LSS patients who do not respond adequately to conservative therapies.

Lumbar interbody fusion (LIF) is commonly employed to treat various spinal pathologies, particularly lumbar spinal stenosis. Currently, LIF can be performed via open or minimally invasive approaches, including transforaminal, posterior, anterior, and lateral routes, each with its own advantages and disadvantages. Generally, posterior lumbar interbody fusion (PLIF) is a well-established procedure associated with good fusion rates and relatively low complication rates. However, it carries the risk of iatrogenic injury to neural structures and paraspinal muscles. Despite demonstrating favorable early outcomes, PLIF has notable limitations, including a relatively high complication rate and a challenging recovery process. In 1982, transforaminal lumbar interbody fusion (TLIF) was introduced, which offers a less traumatic and safer unilateral interbody fusion technique. TLIF addresses several shortcomings of PLIF, leading to its rapid adoption and continuous refinement within the spine surgery community. Nevertheless, traditional open TLIF faces challenges such as significant tissue trauma, potential muscle atrophy, chronic postoperative low back pain, and adjacent segment instability.

The advent of various minimally invasive techniques has helped reduce muscle injury and irritation to the posterior spinal elements. To minimize surgical trauma and facilitate rapid recovery, minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) was developed. A meta-analysis published in 2017 reported that MIS-TLIF could lower postoperative complication rates compared to conventional open procedures. Furthermore, MIS-TLIF demonstrates significant efficacy in protecting muscles (e.g., the multifidus) and ligaments. A comparative study indicated that the rates of postoperative complications and reoperations at 2-year and 3-year follow-ups were significantly lower for MIS-TLIF than for traditional TLIF. However, despite the improved visualization provided by the endoscope in MIS-TLIF, visual blind spots may still exist in certain complex anatomical areas, potentially leading to incomplete assessment of the pathological site and suboptimal placement of internal fixation devices. Additionally, MIS-TLIF relies on traditional open pedicle screw fixation, which may increase the long-term risk of postoperative chronic low back pain.

To address the aforementioned clinical challenges, our research team independently developed a L-Unitary Soft Endoscope minimally invasive system, termed LUSE (Chinese National Invention Patent: CN117017466B). It completed filing as a Class I medical device with the Guangzhou Market Supervision Administration in 2021 (Filing No.: 20210598) and is classified as a set of fundamental orthopedic surgical instruments, with its filing status remaining valid. The system features a highly integrated, all-in-one design that combines key components such as the display, camera, light source, and transmission system into a single unit, simplifying operation and maintenance. During development, particular attention was paid to controlling the size and weight of the endoscope, resulting in a compact and lightweight soft endoscope with a diameter of 1.8 mm and a length of 2-4 cm. Its volume and weight are reduced by approximately 93% compared to traditional endoscopes. This endoscope integrates multiple functions including illumination, imaging, and recording, significantly enhancing procedural convenience and patient comfort.

Compared to the traditional MIS-TLIF performed under a Quadrant expandable retractor system, the highly integrated LUSE system offers several advantages in lumbar minimally invasive fusion surgery: (1) The LUSE system supports 8K ultra-high-definition imaging, providing clear and detailed visualization of the surgical field, whereas the Quadrant retractor system only provides illumination without endoscopic magnification, limiting the ability to visualize fine anatomical structures; (2) LUSE-TLIF utilizes a percutaneous pedicle screw system, minimizing injury to the lumbar back muscles, ligaments, and blood vessels. In contrast, MIS-TLIF requires the placement of pedicle screws via a traditional open approach, which may increase the long-term incidence of chronic back pain; (3) The soft lens of the LUSE system offers 360-degree flexibility, whereas the Quadrant retractor system has inherent visual blind spots that can hinder adequate decompression and optimal implant placement. Therefore, LUSE-TLIF holds multiple advantages over MIS-TLIF. Our team has previously demonstrated the safety and efficacy of the LUSE system in anterior cervical discectomy and fusion (ACDF) and artificial disc replacement (ADR) procedures, with related studies published in leading Chinese journals such as the Chinese Journal of Orthopaedicsand the Chinese Journal of Spine and Spinal Cord. However, there is currently a lack of clinical research in China evaluating the efficacy of LUSE-TLIF for treating LSS. Consequently, this study aims to apply LUSE-TLIF for LSS treatment, observe its safety, efficacy, and clinical outcomes, and conduct a comparative analysis with MIS-TLIF, with the goal of providing spine surgeons with an additional and potentially superior surgical option.

연구 유형

중재적

등록 (추정된)

276

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

    • Guangdong
      • Guangzhou, Guangdong, 중국, 515000
        • 모병
        • The Third Affiliated Hospital of Southern Medical University
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Age ranging from 40 to 70 years, irrespective of sex.
  • Presence of bilateral lower-limb pain and neurogenic claudication, with or without low back pain.
  • Preoperative computed tomography or magnetic resonance imaging confirming single-level lumbar spinal stenosis accompanied by grade II or higher lumbar spondylolisthesis and/or lumbar instability.
  • Persistent pain within 7 days prior to enrollment, with inadequate response to nonsurgical treatment for more than 3 months.
  • Willingness to provide written informed consent and ability to comply with the study protocol and visit schedule.

Exclusion Criteria:

  • Patients with evidence of vascular claudication identified by lower-limb color Doppler ultrasound.
  • Patients with a history of previous lumbar spine surgery.
  • Coexistence of severe lumbar disc herniation, spinal deformity, spinal tumor, infection, or inflammatory diseases.
  • Pregnancy or lactation.
  • Presence of severe underlying medical conditions or psychiatric disorders that preclude tolerance of the procedure.
  • Known concurrent diseases considered by the investigator to preclude study entry.
  • Inability to comply with study assessments or complete questionnaires for any reason.
  • Patients deemed unsuitable for participation in this trial as judged by the investigator.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 삼루타

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: LUSE-TLIF
The subject underwent LUSE-TLIF surgery
LUSE-TLIF is a TLIF procedure performed through the LUSE system.
다른 이름들:
  • 실험군
  • 01
활성 비교기: MIS-TLIF
Subjects underwent MIS-TLIF surgery assisted by the Quadrant channel
MIS-TLIF is a TLIF procedure performed through the Quadrant channel and other systems.
다른 이름들:
  • 대조군
  • 02

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Vertebral Fushion
기간: 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
Assess vertebral fusion status through imaging indicators and clinical symptoms. Vertebral fusion was established as the clinical outcome, defined as: (1) Clinical fusion: a. absence of mechanical low back pain and intermittent claudication; b. dynamic flexion-extension radiographs demonstrating motion angle of the surgical segment less than 4°; (2) Bony fusion: a. Bridwell grade A or B; b. increase in segmental lordosis angle of the surgical segment ≥3° compared to baseline; (3) simultaneous achievement of both clinical and bony fusion.
3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
ODI
기간: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
The ODI score refers to the Oswestry Disability Index, a widely used questionnaire that measures the level of disability in individuals with low back pain. It consists of ten sections assessing daily activities, with scores ranging from 0 to 100; higher scores indicate more severe disability.
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation

2차 결과 측정

결과 측정
측정값 설명
기간
VAS
기간: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
The VAS score refers to the Visual Analogue Scale, a tool used to measure leg and back pain intensity. Patients mark a point on a 10-cm line, where one end represents "no pain" (0) and the other "worst imaginable pain" (10). The distance from the zero point gives the score, providing a simple, quick measure of symptom severity.
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
Surgery time
기간: within 24 hours after surgery
The surgery duration is recorded according to the time in the surgical document, with the unit in minutes.
within 24 hours after surgery
Total blood loss
기간: within 24 hours after surgery
Collect the patient's height (m), weight (kg), hematocrit levels one day before and one day after surgery, and calculate the total blood loss (mL) using the Gross equation and Nadler formula.
within 24 hours after surgery
postoperative drainage volume
기간: Within 24 hours after the subject is discharged
The total drainage volume (mL) will be recorded by a ward nurse who is unaware of the study
Within 24 hours after the subject is discharged
incision length
기간: Within 24 hours after surgery
The incision length (cm) will be measured by a surgical nurse who is unaware of the study.
Within 24 hours after surgery
surgical costs
기간: Within 24 hours after the subject is discharged
Hospitalization costs (yuan/¥) will be calculated by a nurse who is unaware of the study, based on hospital system records.
Within 24 hours after the subject is discharged
intraoperative blood loss
기간: within 24 hours after surgery
Intraoperative blood loss was recorded by a nurse who was unaware of this study, including blood in the drains and in the gauze, measured in mL.
within 24 hours after surgery
Other lumbar spine imaging indicators
기간: baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
Measurement of dural sac cross-sectional area, lumbar spondylolisthesis rate, Cobb angle, average intervertebral disc height, and other parameters using X-ray, CT, and MRI.
baseline, 3-day, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
Condition of paraspinal muscles
기간: baseline, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
MRI measures paraspinal muscle area and fat infiltration rate by analyzing cross-sectional images from the lumbar spine.
baseline, 3-month, 6-month, 1-year, 2-year, 3-year, 5-year post-operation
Muscle injury
기간: 1 day before surgery, 1 day and 3 days after surgery
CK (creatine kinase) and CK-MB are blood biomarkers used to assess muscle damage after lumbar fusion surgery
1 day before surgery, 1 day and 3 days after surgery

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2026년 3월 18일

기본 완료 (추정된)

2031년 12월 31일

연구 완료 (추정된)

2031년 12월 31일

연구 등록 날짜

최초 제출

2026년 4월 24일

QC 기준을 충족하는 최초 제출

2026년 5월 8일

처음 게시됨 (실제)

2026년 5월 14일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 5월 14일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 5월 8일

마지막으로 확인됨

2026년 3월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

Study Protocol, Statistical Analysis Plan, Informed Consent Form

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다